Carregant...
Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
The era of antiangiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway has become a mainstay in the treatment of metastatic renal cell carcinoma (mRCC), showing primary responses in 65–70% of patients. Nevertheless, most of those patients progress to angiogenesis i...
Guardat en:
| Publicat a: | Memo |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Vienna
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5725523/ https://ncbi.nlm.nih.gov/pubmed/29250198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-017-0344-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|